Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.73 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.62 |
| ▸ | ACE | P12821 | 4/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSG | P08311 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565532 | 1.00 | FAAH (0.73) | FAAHPSMB5ACEITGB3ITGA2B | |
| SCHEMBL15155391 | 1.00 | FAAH (0.73) | FAAHPSMB5ACEITGB3ITGA2B | |
| SCHEMBL8467930 | 0.95 | FAAH (0.79) | FAAHPSMB5ACEITGB3ITGA2B | |
| SCHEMBL9666252 | 0.95 | FAAH (0.79) | FAAHPSMB5ACEITGB3ITGA2B | |
| SCHEMBL1815011 | 0.94 | FAAH (0.81) | FAAHPSMB5ITGB3ITGA2B | |
| SCHEMBL22494096 | 0.94 | FAAH (0.81) | FAAHPSMB5ITGB3ITGA2B | |
| SCHEMBL9716617 | 0.94 | FAAH (0.81) | FAAHPSMB5ITGB3ITGA2B | |
| SCHEMBL22494095 | 0.94 | FAAH (0.81) | FAAHPSMB5ITGB3ITGA2B | |
| SCHEMBL22494097 | 0.94 | FAAH (0.81) | FAAHPSMB5ITGB3ITGA2B | |
| SCHEMBL9506671 | 0.94 | FAAH (0.81) | FAAHPSMB5ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| CN-107041139-A | The derivative of sea hare proline sea hare isoleucine peptide | 艾更斯司股份有限公司 | 2017-08-11 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2013114173-A1 | A NOVEL PROCESS FOR THE PREPARATION OF SITAGLIPTIN | SMILAX LABORATORIES LIMITED (IN) | 2013-08-08 | — | — | WO | claimed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4043076-B1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORP (JP) | 2024-06-26 | — | — | EP | disclosed |
| EP-4386090-A1 | METHOD FOR DETERMINING AND IMPROVING THE POTENTIAL EFFICACY OF ANTICANCER TREATMENT | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2024-06-19 | — | — | EP | disclosed |
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | GENEFRONTIER CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| CN-116926140-A | A fatty acylated amino acid with effect of enhancing or improving food taste, and its preparation method | 华南理工大学 | 2023-10-24 | — | — | CN | disclosed |
| US-11527306-B2 | Streamlined method for analytical validation of biochemicals detected using an untargeted mass-spectrometry platform | METABOLON, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| CN-115340468-A | (R) -deuterated phenylalanine derivative and preparation method thereof | 西南大学 | 2022-11-15 | — | — | CN | disclosed |
| US-20140127144-A1 | Flavour Modifying Compounds | GIVAUDAN S. A. (CH) | 2014-05-08 | — | — | US | disclosed |
| US-20140127144-A1 | Flavour Modifying Compounds | GIVAUDAN S. A. (CH) | 2014-05-08 | — | — | US | disclosed |
| WO-2013114173-A1 | A NOVEL PROCESS FOR THE PREPARATION OF SITAGLIPTIN | SMILAX LABORATORIES LIMITED (IN) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013010991-A1 | FLAVOUR MODIFYING COMPOUNDS | GIVAUDAN SA (CH) | 2013-01-24 | — | — | WO | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127144-A1 | Flavour Modifying Compounds | TAS2R1, TAS1R2, TAS2R5 | FAAH 1516/4885PSMB5 973/4885ACE 2482/4885 |
| US-20240092836-A1 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | CXCL10, CXCR3, CXCR6 | FAAH 4675/4885PSMB5 1866/4885ACE 3306/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | FAAH 4536/4885PSMB5 2150/4885ACE 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.